CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

Abstract To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportuniti...

Full description

Saved in:
Bibliographic Details
Published in:Nucleic acids research 2022-01, Vol.50 (D1), p.D1184-D1199
Main Authors: Liu, Zhongyang, Liu, Jiale, Liu, Xinyue, Wang, Xun, Xie, Qiaosheng, Zhang, Xinlei, Kong, Xiangya, He, Mengqi, Yang, Yuting, Deng, Xinru, Yang, Lele, Qi, Yaning, Li, Jiajun, Liu, Yuan, Yuan, Liying, Diao, Lihong, He, Fuchu, Li, Dong
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers, Pharmacological
Database Issue
Databases, Genetic
Drug Resistance, Neoplasm - genetics
Gene Expression Regulation, Neoplastic - drug effects
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Transcriptome - genetics
Tumor Microenvironment - drug effects
Tumor Microenvironment - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportunities for exploring molecular determinants of drug response, but meanwhile pose challenges for data management, integration, and reuse. Here we present the Cancer Treatment Response gene signature DataBase (CTR-DB, http://ctrdb.ncpsb.org.cn/), a unique database for basic and clinical researchers to access, integrate, and reuse clinical transcriptomes with cancer drug response. CTR-DB has collected and uniformly reprocessed 83 patient-derived pre-treatment transcriptomic source datasets with manually curated cancer drug response information, involving 28 histological cancer types, 123 drugs, and 5139 patient samples. These data are browsable, searchable, and downloadable. Moreover, CTR-DB supports single-dataset exploration (including differential gene expression, receiver operating characteristic curve, functional enrichment, sensitizing drug search, and tumor microenvironment analyses), and multiple-dataset combination and comparison, as well as biomarker validation function, which provide insights into the drug resistance mechanism, predictive biomarker discovery and validation, drug combination, and resistance mechanism heterogeneity.
ISSN:0305-1048
1362-4962
DOI:10.1093/nar/gkab860